OBI Pharma's OBI-3424, which is being developed to treat patients with acute lymphoblastic leukemia, was granted orphan drug status by the FDA.
OBI's acute lymphoblastic leukemia candidate gets FDA orphan status
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.